The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
Identifieur interne : 000132 ( France/Analysis ); précédent : 000131; suivant : 000133The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
Auteurs : Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-04.
English descriptors
Abstract
Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non‐ergot selective D2/D3 agonist with α2 antagonist properties shown to be effective in the treatment of PD. This 12‐month international, randomized, double‐blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS III, Items 18–31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow‐up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12‐month study duration was observed both in the piribedil and bromocriptine groups (−7.9 ± 9.7 points from baseline versus −8.0 ± 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long‐term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long‐term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20750
Affiliations:
- Allemagne, Argentine, Belgique, Espagne, France, Italie, Portugal, Royaume-Uni
- Angleterre, Midlands de l'Ouest
- Birmingham, Créteil
Links toward previous steps (curation, corpus...)
- to stream Main, to step Corpus: 000880
- to stream Main, to step Curation: 000768
- to stream Main, to step Exploration: 001185
- to stream France, to step Extraction: 000132
Links to Exploration step
ISTEX:1D2A61A7276EAF947FA7688AEC063C396BB88CB1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease</title><author><name sortKey="Castro Aldas, Alexandre" sort="Castro Aldas, Alexandre" uniqKey="Castro Aldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name></author><author><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name></author><author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name></author><author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name></author><author><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name></author><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name></author><author><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:1D2A61A7276EAF947FA7688AEC063C396BB88CB1</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1002/mds.20750</idno><idno type="url">https://api.istex.fr/document/1D2A61A7276EAF947FA7688AEC063C396BB88CB1/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000880</idno><idno type="wicri:Area/Main/Curation">000768</idno><idno type="wicri:Area/Main/Exploration">001185</idno><idno type="wicri:Area/France/Extraction">000132</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease</title><author><name sortKey="Castro Aldas, Alexandre" sort="Castro Aldas, Alexandre" uniqKey="Castro Aldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name><affiliation wicri:level="1"><country xml:lang="fr">Portugal</country><wicri:regionArea>Instituto de Ciências da Saúde, Universidade Católica Portuguesa, Lisboa</wicri:regionArea><wicri:noRegion>Lisboa</wicri:noRegion></affiliation></author><author><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name><affiliation wicri:level="1"><country xml:lang="fr">Belgique</country><wicri:regionArea>CHR de la Citadelle, Service de Neurologie, Liège</wicri:regionArea><wicri:noRegion>Liège</wicri:noRegion></affiliation></author><author><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Deutsche Klinik für Diagnostik, Wiesbaden</wicri:regionArea><wicri:noRegion>Wiesbaden</wicri:noRegion><wicri:noRegion>Wiesbaden</wicri:noRegion></affiliation></author><author><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name><affiliation wicri:level="1"><country xml:lang="fr">Argentine</country><wicri:regionArea>Fleni, Instituto de Investigaciones Neurologicas Raul Carrera Montaneses, Buenos Aires</wicri:regionArea><wicri:noRegion>Buenos Aires</wicri:noRegion></affiliation></author><author><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name><affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Queen Elisabeth Hospital, Neurology Research, Birmingham</wicri:regionArea><placeName><settlement type="city">Birmingham</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Midlands de l'Ouest</region></placeName></affiliation></author><author><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name><affiliation wicri:level="1"><country xml:lang="fr">Italie</country><wicri:regionArea>Università degli Studi, Clinica Neurologica, Bari</wicri:regionArea><wicri:noRegion>Bari</wicri:noRegion></affiliation></author><author><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name><affiliation wicri:level="1"><country xml:lang="fr">Espagne</country><wicri:regionArea>Hospital Mutua de Terrassa, Servicio de Neurologia, Terrassa</wicri:regionArea><wicri:noRegion>Terrassa</wicri:noRegion></affiliation></author><author><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Institut de Recherches Internationales Servier (IRIS), Courbevoie</wicri:regionArea><wicri:noRegion>Courbevoie</wicri:noRegion><wicri:noRegion>Courbevoie</wicri:noRegion></affiliation></author><author><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name><affiliation wicri:level="1"><country xml:lang="fr">France</country><wicri:regionArea>Service de Neurologie, Centre Hospitalier Universitaire H. Mondor, Créteil</wicri:regionArea><placeName><settlement type="city">Créteil</settlement></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2006-04">2006-04</date><biblScope unit="volume">21</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="500">500</biblScope><biblScope unit="page" to="509">509</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">1D2A61A7276EAF947FA7688AEC063C396BB88CB1</idno><idno type="DOI">10.1002/mds.20750</idno><idno type="ArticleID">MDS20750</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>bromocriptine</term><term>dopamine agonists</term><term>levodopa</term><term>piribedil</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Dopamine agonists have been recommended as early treatment for Parkinson's disease (PD), alone or combined with levodopa. Piribedil is a non‐ergot selective D2/D3 agonist with α2 antagonist properties shown to be effective in the treatment of PD. This 12‐month international, randomized, double‐blind trial aimed to assess the efficacy of piribedil 150 mg versus bromocriptine 25 mg, in early combination with levodopa in Stage I to III PD patients. Motor efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS III, Items 18–31) as improvement from baseline. Response rate was defined as a 30% improvement. Among the 425 randomly assigned patients, 178 were also included in a substudy on cognitive follow‐up evaluated by a dysexecutive syndrome oriented battery. A relevant improvement in UPDRS III over the 12‐month study duration was observed both in the piribedil and bromocriptine groups (−7.9 ± 9.7 points from baseline versus −8.0 ± 9.5; not significant [n.s.]) with a response rate of 58.4% and 55.3% (n.s.), respectively. Piribedil and bromocriptine resulted in similar improvement on all UPDRS III subscores. Piribedil patients required less levodopa dose increase than those on bromocriptine. Cognitive performance remained generally unchanged in both groups, with a significant effect of piribedil limited to the Wisconsin Card Sorting Test. An overall good tolerability of piribedil was observed. Early combination of piribedil 150 mg with levodopa resulted in significant long‐term improvement of all motor symptoms in PD patients insufficiently controlled by levodopa alone. Taking into account both efficacy and acceptability in the long‐term, piribedil proved in this bromocriptine controlled study to be an effective and safe treatment for PD. © 2005 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Argentine</li><li>Belgique</li><li>Espagne</li><li>France</li><li>Italie</li><li>Portugal</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Midlands de l'Ouest</li></region><settlement><li>Birmingham</li><li>Créteil</li></settlement></list><tree><country name="Portugal"><noRegion><name sortKey="Castro Aldas, Alexandre" sort="Castro Aldas, Alexandre" uniqKey="Castro Aldas A" first="Alexandre" last="Castro-Caldas">Alexandre Castro-Caldas</name></noRegion></country><country name="Belgique"><noRegion><name sortKey="Delwaide, Paul" sort="Delwaide, Paul" uniqKey="Delwaide P" first="Paul" last="Delwaide">Paul Delwaide</name></noRegion></country><country name="Allemagne"><noRegion><name sortKey="Jost, Wolfgang" sort="Jost, Wolfgang" uniqKey="Jost W" first="Wolfgang" last="Jost">Wolfgang Jost</name></noRegion></country><country name="Argentine"><noRegion><name sortKey="Merello, Marcelo" sort="Merello, Marcelo" uniqKey="Merello M" first="Marcelo" last="Merello">Marcelo Merello</name></noRegion></country><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Williams, Adrian" sort="Williams, Adrian" uniqKey="Williams A" first="Adrian" last="Williams">Adrian Williams</name></region></country><country name="Italie"><noRegion><name sortKey="Lamberti, Paolo" sort="Lamberti, Paolo" uniqKey="Lamberti P" first="Paolo" last="Lamberti">Paolo Lamberti</name></noRegion></country><country name="Espagne"><noRegion><name sortKey="Aguilar, Miguel" sort="Aguilar, Miguel" uniqKey="Aguilar M" first="Miguel" last="Aguilar">Miguel Aguilar</name></noRegion></country><country name="France"><noRegion><name sortKey="Del Signore, Susanna" sort="Del Signore, Susanna" uniqKey="Del Signore S" first="Susanna" last="Del Signore">Susanna Del Signore</name></noRegion><name sortKey="Cesaro, Pierre" sort="Cesaro, Pierre" uniqKey="Cesaro P" first="Pierre" last="Cesaro">Pierre Cesaro</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/France/Analysis
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000132 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/France/Analysis/biblio.hfd -nk 000132 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= France
|étape= Analysis
|type= RBID
|clé= ISTEX:1D2A61A7276EAF947FA7688AEC063C396BB88CB1
|texte= The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |